Featured Research

from universities, journals, and other organizations

Promising New Parkinson's Treatment Proves Safe

Date:
April 26, 2000
Source:
American Academy Of Neurology
Summary:
An experimental drug that may improve Parkinson's disease symptoms when used in conjunction with current therapies is safe for use by Parkinson's patients, according to a study published by the Parkinson Study Group in the April 25 issue of Neurology, the American Academy of Neurology's scientific journal.

An experimental drug that may improve Parkinson's disease symptoms when used in conjunction with current therapies is safe for use by Parkinson's patients, according to a study published by the Parkinson Study Group in the April 25 issue of Neurology, the American Academy of Neurology's scientific journal.

Researchers found that Parkinson's disease patients did not improve when using the drug -- remacemide hydrochloride -- alone. However, recent preliminary studies have shown that remacemide hydrochloride, used in addition to currently prescribed dopaminergic drugs, such as levodopa, reduces Parkinson's disease symptoms and may slow disease progression.

"Our primary goal was to learn how to use the drug safely," said neurologist and study corresponding-author Steven Schwid, MD, at the University of Rochester in New York. "If ongoing studies confirm that remacemide used in conjunction with dopaminergic therapy improves patients' symptoms, it may be the first of a new class of Parkinson's therapies. If it is also proved to have neuroprotective qualities by preventing the progression of the disease, it could be an even more significant advance in the treatment of Parkinson's disease."

The study included 200 patients with early Parkinson's who were not taking levodopa or other dopamine drugs. Patients received 150, 300 or 600 mg of remacemide hydrochloride or placebo (inactive pill) daily for five weeks. Patients who could not tolerate the daily amount in the prescribed two dosages were allowed to divide the daily amount into four doses.

Of the patients receiving the 300 and 600 mg dosages, 85 percent were able to complete the study on their assigned dosage. Ninety-six percent of those taking 150 mg and 98 percent of those receiving placebo completed the study. Some patients reported nausea and dizziness, but no serious side effects were noted.

Rating scales used to evaluate patients' mental function, mobility and ability to complete common daily activities remained stable among patients receiving remacemide.

"Research has suggested that over-activity of a neurotransmitter in the brain called glutamate, contributes to some signs and symptoms of Parkinson's," Schwid explained. "Glutamate causes excitation of certain brain cells or neurons, which may lead to brain cell death and Parkinson's progression. Reducing glutamate activity in the brain might improve Parkinson's symptoms and slow worsening of the disease."

Remacemide hydrochloride interferes with glutamate activity and has improved symptoms in animal models of Parkinson's disease. The drug also has been used in clinical trials for epilepsy, acute stroke and Huntington's disease. Parkinson's disease, a chronic neurologic disease that impairs mobility, is caused, in part, by a progressive loss of dopamine producing brain cells. While treatment with dopaminergeric drugs, such as levodopa, have provided substantial relief for most patients with Parkinson's disease, the drugs tend to be less effective in treating fluctuating symptoms after five years. The study was performed by the Parkinson Study Group at 21 medical centers nationwide, in a collaborative effort to gather and analyze Parkinson's data, and was supported by Astra Pharmaceuticals.

###

The American Academy of Neurology, an association of more than 16,500 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. For more information about the American Academy of Neurology, visit its Web site at http://www.aan.com. For online neurological health and wellness information, visit NeuroVista at http://www.aan.com/neurovista.


Story Source:

The above story is based on materials provided by American Academy Of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy Of Neurology. "Promising New Parkinson's Treatment Proves Safe." ScienceDaily. ScienceDaily, 26 April 2000. <www.sciencedaily.com/releases/2000/04/000426081102.htm>.
American Academy Of Neurology. (2000, April 26). Promising New Parkinson's Treatment Proves Safe. ScienceDaily. Retrieved July 26, 2014 from www.sciencedaily.com/releases/2000/04/000426081102.htm
American Academy Of Neurology. "Promising New Parkinson's Treatment Proves Safe." ScienceDaily. www.sciencedaily.com/releases/2000/04/000426081102.htm (accessed July 26, 2014).

Share This




More Health & Medicine News

Saturday, July 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins